News

Korlym controls hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are

The BARDA contract includes pre-clinical efficacy and toxicology studies; clinical studies; manufacturing activities; and associated regulatory activities of TP-434. The contract includes a 12-month base period with committed

Each of the eleven products will deliver the full nutritional or vitamin dosage over a period of time from 12 to 24 hours, the company said. The company

NCCN has received a research grant from AVEO and Astellas to evaluate the role of tivozanib in the treatment of solid tumors. Tivozanib is a potent, selective, long

Dey is conducting business as Mylan Specialty effective immediately, the company said. Dey Pharma will continue to be used as the legal entity until all required transition steps

Alpha-synuclein is a protein whose clumping is the pathological sign of Parkinson’s disease (PD). NeuroPhage Preclinical R&D senior vice president Kimberley S Gannon said the grant will provide

The solution has been selected by Interface Children & Family Services of Camarillo, Hope by the Sea of Laguna Niguel, Quapaw House, of Hot Springs, and St. Louis

The Canadian patent covers Polyanhydrides which links low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into

The study protocol was reviewed and cleared by the FDA and Health Canada. RedHill has submitted an IND to the FDA and Clinical Trial Application (CTA) to Health